Figure 2From: Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model Severity of clinical deficits in MOG peptide EAE is diminished by astroglial CXCL10 deletion. (A) Average daily clinical scores and (B) sum of clinical scores of mGFAPcre/CXCLfl/fl (CXCL10 knockout) and CXCLfl/fl littermate (control) mice induced with MOG peptide EAE. Data are shown as means ± SEMs; statistical significance was determined by Wilcoxon-Mann-Whitney test, (n = 14, P = 0.007).Back to article page